Noble Capital initiated coverage of Oncology Institute (TOI) with an Outperform rating and $8 price target The medical practice management company specializing in community-based oncology practices manages and operates oncology clinics in five states, notes the analyst, who believes that trends in cost containment “will work in TOI’s favor.” The firm estimates FY26 revenues of $583.4M, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOI:
- Oncology Institute initiated with a Buy at B. Riley
- Oncology Institute names Kristin England chief administrative officer
- Oncology Institute to be exclusive oncology provider for SilverSummit Healthplan
- Oncology Institute files $50M common stock offering
- Oncology Institute management to meet virtually with B. Riley